尿激酶受体
癌症研究
巨噬细胞极化
成纤维细胞生长因子
下调和上调
车站3
信号转导
成纤维细胞生长因子受体
结直肠癌
纤溶酶原激活物抑制剂-1
成纤维细胞生长因子受体2
免疫系统
肿瘤微环境
癌症
生物
巨噬细胞
受体
医学
化学
纤溶酶原激活剂
免疫学
内科学
细胞生物学
体外
生物化学
基因
作者
Yiming Li,Yongkang Shi,Xiuyuan Zhang,Piao Li,Li Ma,Pengbo Hu,Liang Xu,Yu‐Hong Dai,Xia Shu,Hong Qiu
标识
DOI:10.1016/j.bbadis.2023.166665
摘要
Fibroblast growth factor receptor 2 (FGFR2) is frequently activated by overexpression or mutation, and an abnormal fibroblast growth factor (FGF)/FGFR signaling pathway is associated with the occurrence, development, and poor prognosis of colorectal cancer (CRC). Our preliminary analysis found that plasminogen activator inhibitor-1 (PAI-1) expression may be related to FGF/FGFR signaling, however, their role in the tumor immune microenvironment remains unclear. In this study, we observed markedly higher PAI-1 expression in CRC patients with poor survival rates. PAI-1 is regulated by FGF/FGFR2 in colon cancer cells and is involved in M2 macrophage polarization. Mechanistically, inhibiting the JAK2/STAT3 signaling pathway could cause PAI-1 downregulation. Furthermore, the activation of phosphorylated STAT3 upregulated PAI-1. In vivo, FGFR2 overexpression in tumor-bearing mouse models suggested that a PAI-1 inhibitor could rescue FGFR2/PAI-1 axis-induced M2 macrophage polarization, which leads to effective immune activity and tumor suppression. Moreover, the combination of a PAI-1 inhibitor and anti-PD-1 therapy exhibited superior antitumor activity in mice. These findings offer novel insights into the molecular mechanisms underlying tumor deterioration and provide potential therapeutic targets for CRC treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI